Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$49.01
+1.3%		$49.14
$25.17
▼
$55.67
$8.23B0.342.23 million shs281,017 shs
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$83.90
0.0%		$57.94
$25.83
▼
$84.08
$8.90B0.122.29 million shs707,497 shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$12.20
+0.7%		$13.20
$11.36
▼
$15.67
$10.17B0.292.40 million shs983,870 shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$65.13
-0.3%		$61.29
$47.21
▼
$85.25
$2.81B0.53742,228 shs325,596 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
-2.50%-3.32%-12.40%+38.24%+82.18%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-0.10%+0.35%+0.47%+123.91%+194.15%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-0.31%+2.28%-17.21%-8.49%-9.21%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
+6.59%+9.72%-7.40%+6.73%+56.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$49.01
+1.3%		$49.14
$25.17
▼
$55.67
$8.23B0.342.23 million shs281,017 shs
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$83.90
0.0%		$57.94
$25.83
▼
$84.08
$8.90B0.122.29 million shs707,497 shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$12.20
+0.7%		$13.20
$11.36
▼
$15.67
$10.17B0.292.40 million shs983,870 shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$65.13
-0.3%		$61.29
$47.21
▼
$85.25
$2.81B0.53742,228 shs325,596 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
-2.50%-3.32%-12.40%+38.24%+82.18%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-0.10%+0.35%+0.47%+123.91%+194.15%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-0.31%+2.28%-17.21%-8.49%-9.21%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
+6.59%+9.72%-7.40%+6.73%+56.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.72
Moderate Buy$54.5612.80% Upside
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2.24
Hold$81.00-3.48% Downside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
1.67
ReduceN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2.78
Moderate Buy$90.1738.02% Upside

Current Analyst Ratings Breakdown

Latest TARS, RDY, CRNX, and ALKS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/31/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$100.00 ➝ $98.00
7/30/2026
Alkermes plc stock logo
ALKS
Alkermes
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
7/29/2026
Alkermes plc stock logo
ALKS
Alkermes
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$60.00 ➝ $61.00
7/29/2026
Alkermes plc stock logo
ALKS
Alkermes
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$48.00 ➝ $58.00
7/28/2026
Alkermes plc stock logo
ALKS
Alkermes
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$43.00 ➝ $65.00
7/28/2026
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$55.00 ➝ $85.00
7/27/2026
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/23/2026
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C) ➝ Hold (C-)
7/21/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$90.00 ➝ $89.00
7/20/2026
Alkermes plc stock logo
ALKS
Alkermes
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00 ➝ $63.00
7/17/2026
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.67B4.87$1.63 per share29.63$10.78 per share4.49
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$7.70M1,156.03N/AN/A$11.24 per share7.47
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$3.58B2.83$0.85 per share14.33$4.90 per share2.47
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$451.36M6.23N/AN/A$8.09 per share8.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$241.66M$0.38127.29201.54N/A3.96%4.15%2.19%N/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$465.32M-$5.04N/AN/AN/A-1,189.88%-44.22%-39.77%N/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$456M$0.4427.5620.552.4410.15%9.49%6.32%10/23/2026 (Estimated)
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$66.42M-$1.14N/A25.72N/A-9.02%-14.19%-8.89%N/A

Latest TARS, RDY, CRNX, and ALKS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$0.1918-$0.43-$0.2382-$0.43$169.68 million$173.91 million
8/3/2026Q2 2026
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$1.18-$1.14+$0.04-$1.14$14.84 million$25.12 million
7/23/2026Q1 26/27
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.0918$0.06-$0.0318$0.06$850.56 million$850.26 million
5/12/2026Q4 25/26
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.09$0.06-$0.03-$0.03$886.58 million$852.55 million
5/7/2026Q1 2026
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$1.22-$1.23-$0.01-$1.23$8.51 million$10.73 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.060.49%+6.96%13.64%N/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
0.82
2.30
1.85
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/A
15.57
18.56
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.03
1.90
1.39
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
0.21
3.74
3.71

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
98.51%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.85%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
90.01%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.59%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
3.80%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
9.64%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,050167.76 million160.06 millionOptionable
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
210106.07 million102.04 millionOptionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,527834.67 million817.97 millionOptionable
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
5043.02 million38.88 millionOptionable

Recent News About These Companies

Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highlights: Record XDEMVY Sales and ...
August 6 at 12:08 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tarsus-pharmaceuticals-inc-tars-q2-190211100.html
Tarsus projects $685M-$705M in 2026 XDEMVY net product sales while advancing Alkeus acquisition
August 6 at 12:08 AM  |  seekingalpha.comhttps://seekingalpha.com/news/4628178-tarsus-projects-685m-705m-in-2026-xdemvy-net-product-sales-while-advancing-alkeus-acquisition
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript
August 6 at 3:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4932294-tarsus-pharmaceuticals-inc-tars-q2-2026-earnings-call-transcript
Tarsus Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 6 at 2:32 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4932263-tarsus-pharmaceuticals-inc-2026-q2-results-earnings-call-presentation
Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug
August 6 at 2:08 PM  |  fiercebiotech.comF
Tarsus Pharmaceuticals to buy Alkeus Pharmaceuticals
August 6 at 2:08 PM  |  msn.comhttps://www.msn.com/en-us/money/general/tarsus-pharmaceuticals-to-buy-alkeus-pharmaceuticals/ar-AA29wYyt
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
August 6 at 2:08 PM  |  msn.comhttps://www.msn.com/en-us/money/general/tarsus-to-expand-eye-disease-pipeline-with-up-to-800-million-alkeus-acquisition/ar-AA29wNrk
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
August 6 at 9:21 AM  |  zacks.comhttps://www.zacks.com/stock/news/2969638/tarsus-pharmaceuticals-inc-tars-reports-q2-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2969638
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
August 6 at 7:03 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340128/0/en/tarsus-reports-second-quarter-2026-financial-results-advances-next-phase-of-growth.html
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
August 6 at 7:02 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340126/0/en/tarsus-pharmaceuticals-announces-oversubscribed-125-0-million-private-placement-equity-financing.html
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
August 6 at 7:01 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340125/0/en/tarsus-pharmaceuticals-to-acquire-alkeus-pharmaceuticals-and-advance-eye-care-leadership-position.html
Tarsus Pharmaceuticals to Host Second Quarter 2026 Financial Results Webcast and Corporate Update
August 5 at 8:11 PM  |  quiverquant.comQ
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
August 5 at 8:02 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3339874/0/en/tarsus-to-report-second-quarter-2026-financial-results-on-thursday-august-6-2026.html
Tarsus Pharmaceuticals, Inc. $TARS Shares Acquired by Janus Henderson Group PLC
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-tarsus-pharmaceuticals-inc-tars-shares-acquired-by-janus-henderson-group-plc-2026-08-01/
Mizuho Cuts Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $98.00
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/mizuho-cuts-tarsus-pharmaceuticals-nasdaqtars-price-target-to-9800-2026-07-31/
252,588 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Tri Locum Partners LP
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-252588-shares-in-tarsus-pharmaceuticals-inc-tars-purchased-by-tri-locum-partners-lp-2026-07-30/
Tarsus Pharmaceuticals (TARS) Projected to Release Earnings on Thursday
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tarsus-pharmaceuticals-tars-projected-to-release-earnings-on-thursday-2026-07-30/
Healthcare of Ontario Pension Plan Trust Fund Sells 53,030 Shares of Tarsus Pharmaceuticals, Inc. $TARS
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-healthcare-of-ontario-pension-plan-trust-fund-sells-53030-shares-of-tarsus-pharmaceuticals-inc-tars-2026-07-30/
Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
July 29, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2963348/tarsus-pharmaceuticals-inc-tars-may-report-negative-earnings-know-the-trend-ahead-of-q2-release?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_9-2963348
Ally Bridge Group NY LLC Acquires Shares of 80,859 Tarsus Pharmaceuticals, Inc. $TARS
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ally-bridge-group-ny-llc-acquires-shares-of-80859-tarsus-pharmaceuticals-inc-tars-2026-07-29/
Rock Springs Capital Management LP Sells 35,165 Shares of Tarsus Pharmaceuticals, Inc. $TARS
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-rock-springs-capital-management-lp-sells-35165-shares-of-tarsus-pharmaceuticals-inc-tars-2026-07-28/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alkermes stock logo

Alkermes NASDAQ:ALKS

$49.01 +0.64 (+1.33%)
As of 12:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Crinetics Pharmaceuticals stock logo

Crinetics Pharmaceuticals NASDAQ:CRNX

$83.90 -0.03 (-0.03%)
As of 12:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$12.20 +0.09 (+0.70%)
As of 12:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Tarsus Pharmaceuticals stock logo

Tarsus Pharmaceuticals NASDAQ:TARS

$65.12 -0.21 (-0.31%)
As of 12:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas